Ravulizumab-related meningococcal sepsis post rituximab.

Area of Science:

• Neurology
• Immunology
• Infectious Disease

Background:

• Complement inhibition is a key treatment for neuromyelitis optica spectrum disorder (NMOSD), reducing relapses and disability.
• Invasive meningococcal infection is a significant risk associated with complement inhibition therapy.
• Prior immunosuppression, particularly with rituximab, complicates vaccination efficacy and infection risk management in NMOSD patients.

Purpose of the Study:

• To highlight the challenges of meningococcal vaccination in NMOSD patients undergoing complement inhibition therapy after rituximab treatment.
• To present a case of meningococcal sepsis in an NMOSD patient treated with ravulizumab despite vaccination.
• To propose risk management strategies for preventing invasive infections in this vulnerable patient population.

Main Methods:

• Case report of a 17-year-old female patient with severe NMOSD relapse.
• Review of treatment sequencing involving B-cell depletion (rituximab) and complement inhibition (ravulizumab).
• Analysis of vaccination status and subsequent development of meningococcal sepsis.

Main Results:

• The patient experienced a severe NMOSD relapse despite B-cell depletion therapy.
• Meningococcal sepsis developed after initiation of ravulizumab treatment, despite documented vaccination.
• This case underscores the potential for invasive infections even with standard preventive measures.

Conclusions:

• Complement inhibitors are effective for NMOSD but carry infection risks, particularly invasive meningococcal disease.
• Vaccination may not fully protect NMOSD patients treated with complement inhibitors, especially those with prior rituximab exposure.
• Proactive risk assessment and tailored management strategies are crucial for preventing severe infections in NMOSD patients on complement inhibition.